NEW YORK, Oct. 5, 2005 (PRIMEZONE) -- Bioaccelerate Holdings, Inc., (OTCBB:BACL) today announces that it has appointed Dr George Butler, to its board of directors. Dr. Butler will serve as a non-executive director.
Dr. George Butler is formerly the vice president, Customer Relationships, Global Development of AstraZeneca, plc, (NYSE:AZN). Prior to this, he was vice president, head of regulatory affairs. Dr. Butler is a member of the advisory board of The Organization for Professional Regulatory Affairs (TOPRA) and a member of the regulations advisory board of the Centre for Medicines Research International (CMR) -- U.K.
During his career, Dr. Butler has selected, trained, and delivered industry leaders in regulatory affairs, gaining a reputation as amongst the best in the industry. He has delivered, extended, and protected regulatory approvals in cardiovascular, CNS, oncology, gastrointestinal, metabolism, anti-infective, and respiratory areas and achieved simultaneous regulatory applications in U.S., Europe, and Japan with approvals ahead of industry norms with consequent sales line and stock price benefits. Dr. Butler has diverse drug development experience across a wide range of therapeutic areas and has a favorable track record and recognition as one of the top regulatory affairs professionals worldwide. His strategic direction of pharmaceutical product development has led to the approval of multiple drugs in many global markets, notably the USA, E.U., and Japan.
Dr. Butler has also been chairperson and speaker at many industry related meetings, is a fellow of the Royal Society of Medicine (RSM) and a member of the Drug Information Association (DIA).
Prior to his time at AstraZeneca, Dr. Butler was vice president and head of regulatory affairs with Novartis. He has also worked at the most senior level notably on regulatory affairs with Syntex, Bristol-Myers Squibb, Servier Labs, and Glaxo Holdings.
About Bioaccelerate Holdings, Inc.
Bioaccelerate Holdings, Inc. (OTCBB:BACL) is a pharmaceutical development organization ("PDO") that seeks to acquire, develop, and commercialize novel pharmaceutical compounds in an efficient, cost-effective way. Bioaccelerate uses its broad network of academic, industry, and capital market relationships to expedite drug development and raise capital to create and fund its subsidiary companies, which are organized by vertical portfolios in five therapeutic areas: oncology, specialty pharmaceuticals, central nervous system disorders (CNS), cardiovascular disease, and anti-infectives.
Bioaccelerate conducts its business directly and through its subsidiaries. The company holds majority equity interests in 10 biopharmaceutical companies, three of which are public, and holds minority interests in four biopharmaceutical companies, two of which are public. The company also holds a minority equity interest in a public nanotechnology company. Bioaccelerate's strategy relies on its development network for research, clinical development, and project management to guide early-stage compounds from the discovery process through to Phase II/III development where incremental value can be created. Bioaccelerate Holdings, Inc. is listed on the Over-The-Counter Bulletin Board under the symbol "BACL." For more information on Bioaccelerate, visit the company's website at http://www.bioaccelerate.com.
Bioaccelerate Safe Harbor Statement
Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, risks associated with pre-clinical and clinical developments in the biopharmaceutical industry in general and in Bioaccelerate's compounds under development in particular; the potential failure of Bioaccelerate's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Bioaccelerate's compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses, or strategic initiatives that change Bioaccelerate's business, structure, or projections; the development of competing products; uncertainties related to Bioaccelerate's dependence on third parties and partners; and those risks described in the filings with the SEC, all of which are under Bioaccelerate's prior name Mobile Design Concepts, Inc. Bioaccelerate disclaims any obligation to update these forward-looking statements.